Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: Final report of the polish lymphoma research group

Cancer

Volumn 113, Issue 2, 2008, Pages 367-375

  Kalinka Warzocha, Ewa ^a   Wajs, Jaroslaw ^b   Lech Maranda, Ewa ^c   Ceglarek, Bernadette ^d   Holowiecki, Jerzy ^e   Federowicz, Irena ^f   Walewski, Jan ^f   Czyz, Jaroslaw ^g   Robak, Tadeusz ^c   Warzocha, Krzysztof ^d   Centkowski, Piotr ^d   Sulek, Kazimierz ^b   Blasinska Morawiec, Maria ^a   Stellaholowiecka, Beata ^e   Mazur, Grzegorz ^h   Jedrzejczak, Wieslaw W ⁱ   Watek, Marzena ^j   Bilinski, Przemyslaw ^d   Kisiel, Elzbieta ^d  

^a Regional Oncological Centre   (Poland)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^e Department and Clinic of Internal Medicine Diabetology and Nephrology   (Poland)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g MEDICAL UNIVERSITY OF GDANSK   (Poland)

^h WROCLAW MEDICAL UNIVERSITY   (Poland)

ⁱ MEDICAL UNIVERSITY OF WARSAW   (Poland)

^j Regional Oncology Center   (Poland)

more..

Author keywords

Cladribine; International prognostic index; Low grade B cell non Hodgkin lymphoma; Overall survival; Progression free survival; Treatment response

Indexed keywords

CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER GRADING; CANCER REGRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POLAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; POLAND; PREDNISONE; SURVIVAL RATE; VINCRISTINE;

EID: 48349121596     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23558     Document Type: Article

References (31)

1. Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol. 2003;21:5-15.
2. Hoppe R, Kushlan P, Kaplan H, Rosenberg SA, Brown BW. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy and whole body irradiation. Blood. 1981;58:592-598.
3. Dana BW, Dahlberg S, Nathwani BN, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol. 1993;11:644-651.
4. Hagenbeek A, Eghbali H, Monfardini S, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol. 2006;24:1590-1596.
5. Solal-Celigny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1996;14:514-519.
6. Blum KA, Johnson JL, Niedzwiecki D, et al. Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B study 9153. Cancer. 2006;107:2817-2825.
7. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood. 2000;96:2723-2729.
8. Robak T, Blonski J, Gora-Tybor J, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006;108:473-479.
9. Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood. 1995;86:1710-1716.
10. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:1244-1253.
11. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25(suppl 2):11-16.
12. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;15:1110-1117.
13. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516-522.
14. Klasa RJ, Meyer RM, Shustik C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol. 2002;20:4649-4654.
15. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone and dexamethasone: an effective regimen for indolent lymphoma. J Clin Oncol. 1996;14:1262-1268.
16. Lazzarino M, Orlandi E, Montillo M, et al. Fludarabine, cyclophosphamide and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol. 1999;10:59-64.
17. Santini G, Nati S, Spriano M, et al. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica. 2001;86:282-286.
18. Kalinka E, Wajs J, Sulek K, et al. Randomized multicenter trial of cladribine alone (C) or in combination with cyclophosphamide (CC), and COP in previously untreated low grade B-cell non-Hodgkin lymphoma patients: the first interim analysis [abstract]. Blood. 2004;104:3305a.
19. Pigaditou A, Rohatiner AZ, Whelan JS, et al. Fludarabine in low-grade lymphoma. Semin Oncol. 1993;(5 suppl 7):24-27.
20. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-3918.
21. Jurczak W, Rudzki Z, Galazka K, et al. High prevalence of non-Hodgkin's lymphomas in Polish population - 1106 new cases diagnosed according to WHO classification in only 1 district. Pol J Pathol. 2006;57:45-52.
22. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-3732.
23. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.
24. Herold M, Haas A, Srock S, et al. Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma: four year follow-up results of a phase III trial of the East German Study Group Hematology and Oncology [abstract]. Blood. 2006;108:484a.
25. Foussard C, Mounier N, Van Hoof A, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma (FL) patients [abstract]. J Clin Oncol. 2006;24:7508a.
26. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064-3071.
27. Robak T, Smolewski P, Cebula B, Grzybowska-Izydorczyk O, Blonski JZ. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol. 2007;79:107-113.
28. Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski JZ. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer. 2006;107:1542-1550.
29. Ravandi F, O'Brien S. Infections associated with purine analogs and monoclonal antibodies. Blood Rev. 2005;19:253-273.
30. Laszlo D, Galieni P, Raspadori D, et al. Fludarabine-containing regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma. 2000;37:157-161.
31. Tournilhac O, Cazin B, Lepretre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 2004;103:363-365.